Navigation Links
Designing Controls for siRNA ,,, Experiments


Because of its apparent specificity, reproducibility, and ease of use, RNAi technology is greatly accelerating the functional characterization of disease-relevant genes for drug discovery, target validation, and basic research efforts. To ensure the validity of RNAi data, however, proper experimental design and controls are needed. This article outlines some of the critical parameters for performing RNAi experiments in mammalian cultured cells.


Tips for Experimental Design

Carefully Choose Your siRNA Sequence for Maximum Specificity.
Although data indicate that siRNAs are highly specific, it is important to minimize the possibility of off-target effects by designing siRNAs that have limited sequence similarity to genes other than their intended target. Currently, it is not clearly understood how the number and location of mismatches between the antisense siRNA strand and the target mRNA affect silencing. Some reports indicate that a single mismatch in the center of an siRNA sequence can abolish silencing effects (1,2). In fact, this remarkable specificity has been shown in a model system to permit allele specific gene silencing (2). In contrast, another report indicates that siRNAs with regions of 14-15 contiguous bases of sequence similarity between the siRNA and an mRNA can induce silencing (3). Until we develop a better understanding of the specificity of siRNAs for their
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. Designing a Successful qRT-PCR Experiment
2. Designing a Better siRNA
3. Housekeeping Genes: Universal Positive Controls in siRNA Knockdown Experiments
4. RNAi: The Controls You Need
5. Custom and library siRNA for efficient gene silencing
6. Custom and library siRNA for efficient gene silencing
7. Cancer siRNA Oligo Set Version 1.0
8. Library siRNA
9. Custom siRNA Oligo Synthesis Service
10. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
11. Quantification of siRNA Silencing Efficiency Using the LightCycler System
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Designing Controls for siRNA Experiments

(Date:7/2/2008)... develops new therapies based on cells manufacture.../S provide funding round, SALT LAKE CITY and HAMB..., a biotechnology company at the forefront of inno...idney injury, today announced the closing of a,$14...ife Sciences with Novo,A/S joining the syndicate.,...
(Date:7/2/2008).../- Aureus Pharma, a leading provider ...scovery in the life science,industry, announced to...l,be held in Paris on October 23rd and 24th., Thi...inaugural event,which was attended by many of Aure... Europe and North America. The symposium included ...
(Date:7/2/2008)...ance Commercialization of Expanded Portfolio of Va...ANCOUVER, British Columbia, July 2 /-...es Corp. (TSXV: MEV), a company developing and,mar...y announced its name,change and the expansion of i... acquisition of two vascular product development c...
(Date:7/2/2008)...ts to potential of pre-treatment R2 levels as a po...tivity -, TORONTO, July 2 /PRNewswire-FirstCall/ ...Lorus" or the "Corporation"), a biopharmaceutical ...nt of pharmaceutical products and,technologies for...tion by,an Ohio State University (OSU) clinical te...
Breaking Biology Technology:AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 3Aureus Pharma Announces Date of 2008 Annual User Symposium 2Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing 2Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing 3Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing 4Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 3Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 4Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 5
...en the University of Wisconsin-Madison and the Pau...ered a new solution for building nanoelectronics. ...ith because of the complex patterns involved and t...o the scale of individual molecules. , ,Current me... as small as 50 nanometers, a tiny fraction of the...
... and the Wisconsin Technology Council have release... the new economy and the difficulties that still n...tate,s future workforce. , ,Wisconsin Technology ... states such as New Hampshire and Massachusetts ha...rs while Wisconsin has held steady and even gained...
...dison-based rich media systems provider, made two ... 2005, the largest tradeshow and conference in the... is partnering with Vaddio, an automated camera sy...ed and integrated audiovisual presentation system,...es in its line of rich media recorders. , ,In its ...
...umn, we explored the world pharmaceutical market, ...rug blockbusters, super blockbusters and mega bloc...s is on the rise as key Big Pharma companies incre...ive sales forces and globalized pharmaceutical adv...o Big Pharma and a few select other companies. , ,...
Other Biology Technology:Report: Wisconsin still lags in college degrees held by workforce, leads elsewhere 2Report: Wisconsin still lags in college degrees held by workforce, leads elsewhere 3Top 20 big pharmas represent majority of world pharma market 2Top 20 big pharmas represent majority of world pharma market 3
(Date:7/3/2008)...stors of such marine creatures as clams, sand doll...ng 144 million years ago with no clear trend after...rchers. This contradicts previous work showing dra...d may shed light on future diversity., "Some of ...t is happening today from global warming," says Jo...
(Date:7/3/2008)..., 2008 -- Sirtris, a GlaxoSmithKline company focus...ugs to treat diseases of aging such as Type 2 Diab...ted in today,s online edition of Cell Metabolism ...e with resveratrol showed an overall health improv... in cataracts and cardiovascular dysfunction, and ...
(Date:7/3/2008)...hris Smit has concluded that small mammals, such a...opment of natural diversity. Smit researched how s...seems that prickly shrubs are important in protect...ing. Smit has also demonstrated that natural distu...ery important for the diversity of natural areas. ...
(Date:7/2/2008)...h team has published the first clear example of ho...diseases that are normally tolerated singly may co... , In a report issued June 25 by PLoS ONE, an ... examined outbreaks of canine distemper virus (CDV... mortality in Serengeti lions. CDV cycles periodic...
Breaking Biology News(10 mins):Ancient marine invertebrate diversity less explosive than thought 2Ancient marine invertebrate diversity less explosive than thought 3Long-term study of middle-aged mice shows 2Long-term study of middle-aged mice shows 3Tasty meal out of reach 2Big Opportunities Are in the Bag for Food Retailers 13548 1Big Opportunities Are in the Bag for Food Retailers 13548 2ExonHit Therapeutics 2007 Financial Results 3736 1ExonHit Therapeutics 2007 Financial Results 3736 2ExonHit Therapeutics 2007 Financial Results 3736 3ExonHit Therapeutics 2007 Financial Results 3736 4ExonHit Therapeutics 2007 Financial Results 3736 5ExonHit Therapeutics 2007 Financial Results 3736 6ExonHit Therapeutics 2007 Financial Results 3736 7ExonHit Therapeutics 2007 Financial Results 3736 8ExonHit Therapeutics 2007 Financial Results 3736 9ExonHit Therapeutics 2007 Financial Results 3736 10ExonHit Therapeutics 2007 Financial Results 3736 11ExonHit Therapeutics 2007 Financial Results 3736 12Type 2 diabetes may be caused by intestinal dysfunction 13542 1Type 2 diabetes may be caused by intestinal dysfunction 13542 2Type 2 diabetes may be caused by intestinal dysfunction 13542 3Type 2 diabetes may be caused by intestinal dysfunction 13542 4Protein in Human Embryonic Stem Cells Controls Malignant Tumor Cells 13538 1Protein in Human Embryonic Stem Cells Controls Malignant Tumor Cells 13538 2Protein in Human Embryonic Stem Cells Controls Malignant Tumor Cells 13538 3Protein in Human Embryonic Stem Cells Controls Malignant Tumor Cells 13538 4
...cEwen Centre for Regenerative Medicine at Toronto ...s signal that mobilizes specific heart repair cell...a heart attack. , While it has long been known tha...dead tissue after a heart attack, what has not bee... of bone marrow adult stem cells in repairing a da...
...cEwen Centre for Regenerative Medicine at Toronto ...s signal that mobilizes specific heart repair cell...a heart attack. , While it has long been known tha...dead tissue after a heart attack, what has not bee... of bone marrow adult stem cells in repairing a da...
...s from Wageningen University report in this month,...fied a unique genetic fingerprint in the pathogen ...e pathogen possess multiple copies of a specific g...y. Certain potato plants do not recognize strains...aking them susceptible to infection. This is the ...
...d to a rare disease plays a critical role in the b...eak down, new evidence reported in the May Cell Me...nism underlying healthy fat metabolism and explain...anarin-Dorfman Syndrome (CDS), who carry a mutant ...ildup of fat in tissues throughout their bodies. ,...
Other Biology News:A surprise about our body clock 2A surprise about our body clock 3Healing the heart with bone marrow cells 2Healing the heart with bone marrow cells 3Potato blight pathogenicity explained by genome plasticity 2Potato blight pathogenicity explained by genome plasticity 3Gene linked to rare disease activates fat breakdown 2
...t time, you can identify and characterize high-val...tly without interferences. The Agilent Multiple Af...d, multiple high-abundant proteins from human seru...ice. With this revolutionary system, you can: Re...
...olor RNA Spike-In Kit contains in vitro synthesize...neal only to complementary control probes on Agile...dization. The spike-ins serve as a positive microa...TE: This kit is a required component of the Agilen...
...e one mouse-click image analysis software for micr...is the solution for high quality and high throughp...ith VigeneTechs robust algorithms, actual spot bou...ckground correction and dust removal, enhancing th...
...eomic Imaging System, Professional Package Superi...Dynamic Range: The ProXPRESS 2D Proteomic Imaging ... both proteomic and general life science research ...lexibility, enabling the use of all dyes in the UV...
Biology Products: